Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
Momentum Public Relations
Press Release: July 19 2018
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada. Tetra intends on launching this product ahead of the upcoming legalization as it begins to position itself as a player in the natural health product market.
Hemp Energy Drink is developed for those who want to have a clear and focused mind and live an active and fun lifestyle. It can be consumed whenever people are in need of energy whilst working, driving or playing sports and leisure activities. The functional benefits of hemp energy drink are mainly to help for concentration, alertness and to contribute to mental performance and reduction of fatigue.
Hemp Energy Drinks are already available in the U.S.A. and in several European countries, and the European Food Safety Authority confirmed the positive health effects related to the ingredients of Hemp Energy Drink.
Tetra Natural Health has a team of natural health experts that have been preparing to commercialize products containing hemp or that act on the cannabinoid receptors under the existing Food and Drug regulations. To lead and support the team, Tetra recently announced the arrival of Richard Giguere, Executive Vice President Commercial Operations who will implement and oversee the natural health product commercial sales and growth strategy.
Richard has more than 20 years’ experience in sales and marketing including OTC, natural products and original pharmaceutical medications. His arrival was perfectly aligned with Tetra Natural Health’s goal to develop and sell hemp, cannabis and cannabinoid-based OTC (self-care) products to leverage the post-legalization market. Tetra obtained the rights to the TMA and plans on expanding this food product line as part of a structured sales driven growth plan.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc, (TSX-V: TBP) (OTCQB: TBPMF) that is focusing on retail commercialization of hemp, cannabis or cannabinoid-based products authorized by Health Canada for sale.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Natural Health Inc.:
Richard Giguere, Executive Vice President, Commercial Operations
richard.giguere@tetrabiopharma.com
438 899-7575 ext 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
- Published in Tetra Bio Pharma
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed
Momentum Public Relations
Press Release: June 29 2018
Tetra Bio-Pharma Inc.(TBP:V), a leader in cannabinoid-based drug discovery and development, today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model. Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications.
Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market. The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework. Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.
Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community, beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/
Update on North Bud Farms Inc.
Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus. As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations
Momentum Public Relations
Press Release: June 19 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for various pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships through flexibility and efficiency. In the past 10 years, he was also a board member at the companies for which he worked.
“We’re very proud to add Richard Giguere to our senior management team. His vast experience in the sales and marketing of OTC, natural health products and original medications in the pharmaceutical industry across Canada will help drive the execution of our corporate strategy for our Tetra Natural Health and Tetra Veterinary Health divisions,” says Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
Richard Giguere’s arrival is perfectly aligned with Tetra Bio-Pharma’s decision to restructure its corporation by commercial markets. While Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization of cannabinoid-based prescription drugs and treatments, Tetra Natural Health will develop and sell cannabinoid-based OTC (self-care) products to leverage the post-legalization market and Tetra Veterinary Health will focus on commercialization of cannabinoid-based products for the pet product market.
“I am honored to be able to play an active role in growing both the Tetra Natural Health and Tetra Veterinary Health divisions,” says Richard Giguere, EVP, Commercial Operations. “Tetra has a sound business model, and there are significant opportunities for us to grow our two commercial divisions. I am committed to making the best business and commercial decisions to accelerate the development of these huge potential markets for our cannabinoid-based products.”
As a result of this senior management change, Anne-Sophie Courtois left the corporation thereby terminating her role as Vice President, Marketing and Communications.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com
For further information, please contact Tetra Bio-Pharma Inc.
Guy Chamberland, Interim Chief Executive Officer
Guy@tetrabiopharma.com
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 M: 1 514 232 1556
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain
Momentum Public Relations
Press Release: June 18 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada. PPP001 will investigate cannabis as an alternative to fentanyl in the management of breakthrough pain. Santé Cannabis is a Quebec-based medical clinic specialized in clinical research and cannabis – based therapies.
Health Canada approved clinical trials completed by Tetra Bio-Pharma in 2017 and 2018 have led to a significantly improved understanding of the safety, pharmacokinetics and pharmacodynamics of PPP001 in the treatment of pain and suffering. The development of clinical research protocols to investigate the use of cannabis as an alternative to fentanyl followed Tetra’s meeting with the Therapeutic Products Directorate (TPD), Health Canada in early 2018. As a prescription drug, PPP001 will be eligible for insurance coverage.
The trial is designed to assess the time-to-relief in patients suffering from breakthrough pain. Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel alternative to fentanyl. In addition, the time-to-maximal plasma concentrations of THC suggests that PPP001 will provide rapid relief to the patient’s suffering.
“Patients suffering from breakthrough pain require fast relief. Overdosing from fentanyl may occur in patients that exceed the recommended dosage in the hope of obtaining a more rapid relief. The development of a THC-based alternative would help provide a safer option to these patients and help prevent overdosing on fentanyl,” said Dr. Antonio Vigano, an Attending Physician at the Supportive and Palliative Care Division, McGill University Health Centre, an Associate Professor in the department of oncology, McGill University and the Research Director of Santé Cannabis where he is a Principal Investigator in a Phase 3 clinical trial for pain associated with advanced cancer, in addition to a phase 2 trial for chronic pain. “PPP001 has the potential to become the long-awaited alternative to opioids for the management of breakthrough pain in cancer patients. Through this trial we are going to gather more evidence-based data on the safety, efficacy and ease of administration of inhaled cannabinoids as the complementary therapy of choice for cancer related pain.” said Dr. Vigano.
In Canada, the opioid crisis is serious and growing, and imposes devastating effects on families and communities. From January to September 2017, there were at least 2,923 apparent opioid-related deaths of which 92% were accidental. While males make up 76% of these fatalities, the highest percentage (28%) occurred among individuals between the ages of 30 and 39 years.i From January to September 2017, 72% of accidental apparent opioid-related deaths involved fentanyl or fentanyl analogues compared to 55% in 2016.
“Our rich cannabinoid-derived product pipeline has the potential to play a major role in opioid sparing, thus addressing a societal issue of critical proportion,“ said Guy Chamberland, Interim CEO and Chief of Scientific Affairs at Tetra Bio-Pharma. In addition, the R&D team is in discussions with Health Canada to take PPP001 into other therapeutic indications including fibromyalgia. In taking on new therapeutic indications for PPP001 we can, if successful, significantly increase the potential market as well shareholder value,” said Mr. Chamberland.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
About Santé Cannabis
Established in Montreal, Quebec in 2014, Santé Cannabis is a Centre of Excellence in medical cannabis research, clinical practice and healthcare professional training. Since its inception, Santé Cannabis has provided medical assessment, education, monitoring and follow-up to 5000 patients referred by more than 2,000 Quebec physicians. Santé Cannabis operates within the guidelines for the authorization of medical cannabis as set out by the Collège des médecins du Québec. As an independently credentialed clinical trial research organization, and with unparalleled clinical experience supporting both patients and healthcare professionals, Santé Cannabis has established itself as a global leader in medical cannabis research. Santé Cannabis is currently conducting a Health Canada approved Phase 3 trial for PPP001 for advanced cancer patients suffering from uncontrolled pain and associated symptoms, as well as a Phase 2 trial for PPP005 investigating the use of oral capsules of cannabis oil for the treatment of chronic pain. For more information visit www.santecannabis.ca
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Investor Relations Contact:
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Tetra Bio-Pharma Inc.
514-817-2514
Media Contact:
energi PR
Carol Levine
514-288-8500 ext. 226
Stephanie Engel
416-425-9143 ext. 209
———————————-
i https://www.canada.ca/en/health-canada/services/substance-abuse/prescription-drug-abuse/opioids/apparent-opioid-related-deaths.html
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting
Momentum Public Relations
Press Release: June 13 2018
Tetra Bio-Pharma Inc.=(TBP:V) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.
- In Q3 of this year, TBP will file a request to commence a Phase 1 clinical trial for PPP004 our topical product indicated for General Neuropathic Pain, conservatively estimated as a billion-dollar market. Neuropathic pain can be caused by injury or disease and can be associated with such common conditions as shingles, diabetic neuropathy, multiple sclerosis, spinal stenosis and sciatica among other conditions.
- In Q3, we anticipate filing a request to commence a Phase 1 clinical trial for PPP003 an ocular treatment for eye pain and inflammation and dry eye. The company has identified one lead compound that is a non-scheduled 1 cannabinoid which would significantly reduce time to market as is it not considered a controlled substance. TBP is also exploring conducting a study focused on Dry-Eye, in the USA.
- Tetra-Bio-Pharma anticipates launching its Rx Oil capsules for the treatment of chronic pain and cancer pain in Q3 of this year. The company is presently conducting a Phase IV study expected to be completed in Q3 and we expect the launch to occur in Q3.
- We expect to complete our Phase III trial for PPP001 in Q4/2018, Q1/2019 and will file for approval in Q1 of 2019. Tetra will seek additional indications for this product and we will announce our intentions soon.
- In Q3, we expect to launch our bioavailability study for PPP0002, and if we prove equivalence to the referenced product, Tetra anticipates filing for approval under the 505 (B) 2 route in the USA in Q4 2018. In addition, Tetra expects to commence a Phase II study in chronic pain with PPP002 in Q3 of this year.
- Legalization of recreational cannabis is expected to take place in Q3/Q4 of this year following which Tetra Bio-Pharma will launch no fewer than 7 cannabinoid based Natural Health products in the Canadian market. We will also look to license these products worldwide.
“Tetra Bio-Pharma has come a long way in the last 12 months and the momentum is building as we advance our products through various phases of clinical development, thereby answering the need for rigorous scientific evidence. We believe our independently credentialed clinical development work, in combination with the launch of our natural health products will be instrumental in building shareholder value,” stated Guy Chamberland Interim CEO and CSO for Tetra Bio-Pharma.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Executive Vice President, Corporate Development & Licensing
(514) 817-2514
For investors information, please contact:
investors@tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Inc. Announces Changes Relating to the Nomination of its Directors
Momentum Public Relations
Press Release: June 12 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. André Rancourt has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation due to other private business obligations to which he needs to devote his time and attention. The Corporation hereby wishes to withdraw his nomination for election as a director at the upcoming annual meeting of shareholders of the Corporation scheduled to be held on June 19, 2018 (the “Meeting“). Mr. Rancourt will remain as director of the Corporation to complete his current term, which expires at the Meeting, but will not stand for re-election.
Mr. Guy Chamberland, interim Chief Executive Officer of the Corporation, stated: “On behalf of the Corporation, I wish to express our sincere gratitude to André Rancourt for his many years of service and for the excellent contributions that he made to the Corporation while serving as CEO, Director and most recently as Executive Chairman of the Corporation. While we understand André’s motivation for not standing for re-election, he remains a committed and important shareholder”.
The Corporation also became aware of an inadvertent error in the management information circular of the Corporation dated May 22, 2018 and filed on SEDAR on May 25, 2018 in respect of the Meeting (the “Circular“). On page 5 of the Circular, the number of common shares of the Corporation (“Common Shares“) owned or controlled by Mr. André Rancourt was incorrectly stated to be 1,615,000 Common Shares. Tetra wishes to clarify that Mr. Rancourt has not sold any Common Shares and continues to own or exercise control over 6,585,436 Common Share. While Mr. Rancourt will not stand for re-election as director of the Corporation, he will remain an important shareholder of the Corporation and will continue to support the continued success of the Corporation.
The Corporation also wishes to announce that it has filed an amended and restated management information circular, including the notice of the Meeting, with respect to its Meeting (the “Amended Circular“). The Amended Circular replaces and supersedes the Circular. The Amended Circular has been amended to reflect the fact that Mr. Rancourt will not stand for re-election at the Meeting, and to make other consequential amendments.
Except as described above, the A&R Circular remains unchanged from the Original Circular that was mailed to the shareholders of the Company and previously filed on SEDAR. A copy of the Amended Circular is available on SEDAR at www.sedar.com.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE: TBP)(OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx PrincepsTM product offering and inhalation device; guidance on expected sales volumes associated with the Rx PrincepsTM product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation‘s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Tetra Bio-Pharma Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2018/12/c1551.html
Contact:
please contact Tetra Bio-Pharma Inc.: Robert (Bob) Béchard, Vice President, Finance & Business Development, (438) 899-7575; For investors information, please contact: investors@tetrabiopharma.com, (438) 504-5784
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Inc. Strengthens Senior Management Team
Momentum Public Relations
Press Release: June 5 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX-V:TBP) (OTCQB:TBPMF), has strengthened its management team with the promotion of V.P. Financing and Business Development Robert (Bob) Bechard to Executive Vice President, Corporate Development and Licensing, and the hiring of Ofer Yifrach-Stav as Vice President Pharmaceutical Compliance and Quality.
In his new expanded role, Bob will lead Tetra Bio-Pharma’s business development and be actively involved in fundraising and executing the Company’s M&A strategy, while overseeing Investor Relations.
Bob has more than 25 years’ experience in financing, including venture capital and corporate banking along with business development. He was a Senior Member of a Venture Capital fund that delivered top quartile returns investing in North American Biotech companies. During his venture days, he served on the Boards of more than 30 biotech companies and oversaw the negotiation of numerous strategic alliances with major pharmaceutical companies. Additionally, he managed numerous exits via the public market or an outright sale to large pharmaceutical companies on behalf of the venture capital funds. Bob brings sound operational experience from his time as Chief Business Officer for an R&D Management company and VP of Corporate Development for a drug delivery company. As a consultant, he assisted numerous biotech companies in the areas of fundraising, business development, corporate development and strategy.
“We are thrilled to have Bob as an integral member of Tetra Bio-Pharma’s Senior Executive team. His vast experience and extensive international network will help drive the execution of our corporate strategy,” said Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
“I am excited to be able to play a more active role in helping Tetra Bio-Pharma realize its vision to make pharmaceutical grade cannabinoid-based products accessible to patients around the world,” said Bob Bechard, EVP, Corporate Development and Licensing.
The new Vice President Pharmaceutical Compliance and Quality, Ofer Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia. During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance.
“Ofer Yifrach-Stav will play a key role in accelerating our pre-commercial activities in preparation of the marketing applications of PPP001 and PPP002. These activities include production scale-up activities and process validations required to ensure the completeness of the Quality file required for the marketing applications leading to the DIN,” added Guy Chamberland.
The corporation will be restructured to optimize operations by commercial markets. Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization. Tetra Veterinary Health was created for the commercialization of cannabinoid-based products for the pet product market. To take advantage of the post-legalization market, Tetra Natural Health was established to develop and sell cannabinoid-based OTC (self-care) products.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its vision, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Tetra Bio Pharma
Marijuana Stocks Still Have Legs
Momentum Public Relations
Blog: June 1 2018
Marijuana Stocks Still Have Legs
Bryan, Garnier & Co: Global Marijuana Market to Hit US$140 Billion by 2027
Canadian Licensed Producers Expanding Abroad
The exact date when recreational marijuana will be legalized is still uncertain. The Trudeau government has repeatedly said that it will be legalized this summer. When that great day comes to pass it may be the only time in Canadian history that the government has created an economic stimulus package that actually works: the legal marijuana industry.
Not content with only being valued in the billions of dollars in Canada, our domestic marijuana industry is also hell-bent on international expansion.
On January 28, 2018 the CBC ran a story quoting Bloomberg that said there were 87 publicly listed marijuana companies on the TSXV and that collectively they were worth US$37 billion. In January Statistics Canada estimated that almost 5 million Canadians spent $5.7 billion dollars buying marijuana, with only 10% of that going to legal medical cannabis.
On May 28, 2018 Aurora Cannabis announced that it had signed a distribution agreement with German plant based pharmaceutical distributor Heinrich Klenk. Klenk distributes its products in more than 25,000 drug stores across Germany and Europe. Klenk is a trusted name and Aurora has launched a new brand that will be produced in Canada named Cannabis Klenk which the company will distribute. Medical cannabis is legal in Germany.
Aurora has been making international plans and putting them into action for some time. It owns Berlin-based Pedanios, the leading marijuana importer, exporter and distributor of medical marijuana in the European Union as well as 51% of Aurora Nordic which plans on constructing a one million square foot greenhouse in Denmark. To round out its diversified activities the company also owns two companies that specialize in building greenhouse lighting systems, BC Northern Lights and Urban Cultivator.
Aurora is not alone on the international stage, Canopy Growth, which has Snoop Dogg as a spokesman, has operations in seven countries on four continents. Aphria Inc. has operations in more than 10 countries on five continents. It recently created a joint venture, Canninvest Africa with the South African Verve Group of Companies that will see it gain an interest in Verve Dynamics, a licensed producer of medical cannabis extracts, which it believes will become one of if not the lowest cost producer in the extract field.
Driven by economies of scale and the desire to have all the pieces to the puzzle in one place the industry has been consolidating for some time. The most recent example is the merger of Aurora and MedReleaf, which has created the largest marijuana company in the world.
If you think the market is now too high to buy in, you may want to think again. A story published in Forbes on March 1, 2018 predicts a robust and growing legal international marijuana poised for exponential growth.
The story is based on a report by Arcview Market Research which predicts that by 2027 spending on legal recreational and medical marijuana will hit US$57 billion with a 67% market share for recreational marijuana and a 33% share for medical cannabis.
The lion’s share of the revenues will be generated in North America where the largest recreational market is expected to develop with sales going from US$9.2 billion in 2017 to US$47 billion in 2027.
All of which means that serious investors should start doing their due diligence on the marijuana industry now, if they haven’t already. That due diligence should also include bio-pharmas that are developing cannabis- based drugs for regulatory approval and for the over the counter market.
If you still think that marijuana stocks are overpriced you may wish to consider this, investment bank Bryan, Garnier & Co have just predicted that the global marijuana market is poised to grow by a 1,000 percent to hit US$140 billion by 2027.
One of the more interesting set of statistics put out by Statista is that in America, medical marijuana will take a larger slice of the pie than recreational marijuana. The company predicts that by 2025 cannabinoid-based pharmaceuticals will be valued at US$13.2 billion and the legal recreational market at US$10.9 billion.
Whether or not cannabinoid-based pharmaceuticals will surpass the legal recreational market is as yet unknown but predictions like the one above are a sure indication that bio-pharmas launching successful drugs will be lucrative.
A rising tide raises all ships. When Canadian recreational marijuana legalization takes place marijuana stocks are expected to jump and by association so will those pharmaceutical companies developing successful cannabinoid-based drugs.
Tetra Bio-Pharma, (TSXV: TBP) is one such company with a pipeline of cancer chronic pain, and other products under development. Its lead product, PPP 001, trademarked as RX Princeps has started Phase 3 clinical trials and stands to be the first cannabinoid therapy that will have its efficacy and safety proved.
Once that happens, PPP 001 will very likely become the first drug to be given Health Canada and American FDA approval. This achievement will be marked by a Drug Identification Number, DIN, which means that it can legally be prescribed by doctors and eligible for insurance plan coverage. TBP already has distribution agreements in place in Israel and in Europe.
The above does not and should not be taken as investment advice. Investors have the responsibility of performing their own due diligence. In the interests of transparency, Momentum PR represents Tetra Bio-Pharma.
- Published in Blog
Tetra Bio-Pharma Inc. Announces Listing of Warrants
Momentum Public Relations
Press Release: May 30 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that a total of 11,500,000 common share purchase warrants (the “Warrants“) of the Corporation will be listed and posted for trading under the symbol TBP.WT on the TSX Venture Exchange effective on or about June 1, 2018.
The Warrants were issued in connection with the Company’s bought deal prospectus offering of Units (the “Units“) that closed on March 5, 2018. Each Unit consisted of one common share (a “Common Share“) and one Warrant. Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price equal to $1.30 at any time before March 5, 2021.
The Warrants are governed by the terms of a Warrant Indenture dated March 5, 2018 between the Company and Computershare Trust Company of Canada as warrant agent, a copy of which is available under the Company’s profile at www.sedar.com. For further details regarding the Warrants, please refer to the Warrant Indenture.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx PrincepsTM product offering and inhalation device; guidance on expected sales volumes associated with the Rx PrincepsTM product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation‘s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Tetra Bio-Pharma Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2018/30/c3264.html
Contact:
For further information, please contact Tetra Bio-Pharma Inc., Robert (Bob) Béchard, Vice President, Finance & Business Development, (514) 817-2514; For investors information, please contact: investors@tetrabiopharma.com
- Published in Tetra Bio Pharma
Tetra Natural Health Signs a Supply Agreement with Namaste Technologies for the Marketing and Distribution of Rx Princeps™, its Premium Medicinal Cannabis Product
Momentum Public Relations
Press Release: May 17
Tetra Natural Health a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSX-V:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company has signed a Supply Agreement ( the “Supply Agreement”) for the sale and distribution of Rx Princeps™ the medicinal cannabis brand of Tetra Natural Health, a division of Tetra Bio-Pharma (“Tetra Bio-Pharma”)(TSX-V:TBP) (OTCQB:TBPMF), whereby Namaste will purchase Rx Princeps™ from Tetra Natural Health which will be sold through Namaste’s wholly owned subsidiary Access to Cannabis for Medical Purposes (“ACMPR”) medical cannabis “sales-only” facility, Cannmart Inc. (“Cannmart”). The agreement also includes the sales of Tetra Natural Health’s specially designed inhalation device, air filters and its Munchies B Gone gum.
Guy Chamberland, Interim CEO and CSO of Tetra Bio-Pharma comments “We are thrilled to have signed this partnership deal with Namaste who operates as an E-Commerce Medicinal Cannabis distributor with 32 sites in 20 countries, providing substantial exposure for Tetra Natural Health’s Rx Princeps™ brand of premium medicinal cannabis. We believe this is the making of a solid partnership with Tetra Natural Health’s ability to produce a quality product combined with Namaste’s far reaching sales and distribution network”.
Sean Dollinger, President and CEO of Namaste comments; “We are very proud to be bringing on a strong supply partner like Tetra Bio-Pharma. Rx Princeps™ is a unique pharma-based product that we feel will be very valuable for our patients. We have a unique opportunity to develop an exciting platform that will cater specifically to a patient’s needs. We plan on providing a single source for all things cannabis and Cannmart and NamasteMD are key components of that strategy along with securing the highest quality cannabis for our patients. We’d like to take the opportunity to thank Tetra Bio-Pharma management team for their support and look forward to a growing future together.”
Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD).
About Tetra Bio Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
About Namaste Technologies Inc.
Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com
For further information, please contact:
Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
bob@tetrabiopharma.comC 514 817-2514
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
For more information from Namaste Technologies, please contact:
Sean Dollinger, President and Chief Executive Officer
Namaste Technologies Inc.
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com
- Published in Tetra Bio Pharma